13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001224962
Total reported value
$6.7B
$6.7B
106 檔
21.2%
According to the latest 13F quarterly dataset, Perceptive Advisors LLC managed an equity portfolio of $6.7B at the end of Q3 2024, spanning 106 distinct U.S. exchange-listed positions.
Perceptive Advisors LLC executed strategic sector rebalancing during Q3 2024, establishing 15 new positions while fully exiting 18 holdings and trimming 24 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ACLXGBX | Arcellx Inc | Stock-Other | 6.87% | — | -0.03% | |
| 2 | NUVL | Nuvalent Inc-a | Stock-Other | 6.45% | -0.23% | +16.88% | |
| 3 | AM6 | Amicus Therapeutics Inc | Stock-Other | 6.34% | — | — | |
| 4 | IOVA | Iovance Biotherapeutics Inc | Stock-Other | 5.29% | — | +2.64% | |
| 5 | PCVX | Vaxcyte Inc | Stock-Other | 4.90% | — | +8.86% | |
| 6 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 4.15% | — | +180.06% | |
| 7 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 3.95% | +0.28% | +3.30% | |
| 8 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 3.42% | — | — | |
| 9 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 2.51% | — | -5.49% | |
| 10 | APGE | Apogee Therapeutics Inc | Stock-Other | 2.50% | +0.08% | -4.30% | |
| 11 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 2.28% | — | +135.66% | |
| 12 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.13% | -4.08% | EXIT | |
| 13 | ✓ | Immatics NV | Stock-Other | 1.95% | -0.42% | — | |
| 14 | EOLS | Evolus Inc | Stock-Other | 1.84% | +0.16% | -6.90% | |
| 15 | SYRE | Spyre Therapeutics Inc | Stock-Other | 1.79% | +2.03% | -5.23% | |
| 16 | AORT | Artivion Inc | Stock-Other | 1.57% | -0.58% | — | |
| 17 | BHVN | Biohaven Ltd. | Stock-Other | 1.57% | — | — | |
| 18 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 1.51% | — | — | |
| 19 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.49% | -0.06% | +70.51% | |
| 20 | APLT | Applied Therapeutics Inc | Stock-Other | 1.44% | — | — | |
| 21 | CRGX | Cargo Therapeutics Inc | Stock-Other | 1.44% | — | — | |
| 22 | IMVT | Immunovant Inc | Stock-Other | 1.43% | +0.01% | +12.01% | |
| 23 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.42% | -2.59% | +55.16% | |
| 24 | ARGX | Argenx Se - Adr | Stock-Healthcare | 1.36% | — | +661.79% | |
| 25 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.35% | -0.29% | +72.36% | |
| 26 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.32% | -0.05% | +25.53% | |
| 27 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 1.31% | -0.73% | +8.34% | |
| 28 | MGTX | MeiraGTx Holdings plc | Stock-Other | 1.11% | +0.44% | +11.03% | |
| 29 | ALDX | Aldeyra Therapeutics Inc | Stock-Other | 1.06% | — | — | |
| 30 | AKRO | Akero Therapeutics Inc | Stock-Other | 1.04% | — | +14.33% | |
| 31 | SLDB | Solid Biosciences Inc | Stock-Other | 1.02% | +0.11% | — | |
| 32 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 0.90% | — | — | |
| 33 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 0.84% | +0.71% | NEW | |
| 34 | ACRV | Acrivon Therapeutics Inc | Stock-Other | 0.79% | — | — | |
| 35 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.78% | — | -50.91% | |
| 36 | NAUT | Nautilus Biotechnology Inc | Stock-Other | 0.76% | -0.62% | — | |
| 37 | CELC | Celcuity Inc | Stock-Other | 0.75% | -1.95% | — | |
| 38 | PODD | Insulet CORP | Stock-Healthcare | 0.70% | — | — | |
| 39 | ORKA | Oruka Therapeutics Inc | Stock-Other | 0.64% | +0.58% | — | |
| 40 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 0.61% | -0.01% | -3.19% | |
| 41 | OCUL | Ocular Therapeutix Inc | Stock-Other | 0.61% | -0.08% | EXIT | |
| 42 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 0.60% | -0.46% | -5.96% | |
| 43 | NTRA | Natera Inc | Stock-Healthcare | 0.59% | +0.14% | NEW | |
| 44 | CGON | Cg Oncology Inc | Stock-Other | 0.59% | — | — | |
| 45 | ZYME | Zymeworks Inc | Stock-Other | 0.58% | -0.08% | +30.72% | |
| 46 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.55% | -0.75% | — | |
| 47 | ADGM | Adagio Medical Holdings Inc | Stock-Other | 0.54% | -0.12% | — | |
| 48 | ARVN | Arvinas Inc | Stock-Other | 0.54% | — | — | |
| 49 | PRCT | Procept Biorobotics CORP | Stock-Other | 0.54% | — | +49.84% | |
| 50 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 0.52% | -0.17% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | VRNA | Verona Pharma PLC - Adr | +3.3% | +180.06% | Add |
| 2 | NUVL | Nuvalent Inc-a | +1.8% | +16.88% | Add |
| 3 | ACLXGBX | Arcellx Inc | +1.7% | -0.03% | Trim |
| 4 | PCVX | Vaxcyte Inc | +1.5% | +8.86% | Add |
| 5 | VKTX | Viking Therapeutics Inc | +1.4% | +135.66% | Add |
| 6 | 260 | Centessa Pharmaceuticals-adr | +1.3% | +59.72% | Add |
| 7 | ARGX | Argenx Se - Adr | +1.2% | +661.79% | Add |
| 8 | VRDN | Viridian Therapeutics Inc | +0.8% | +72.36% | Add |
| 9 | XBI | Ss Spdr S&p Biotech ETF | +0.8% | +1664.84% | Add |
| 10 | PODD | Insulet CORP | +0.7% | NEW | New buy |
| 11 | PRAX | Praxis Precision Medicines I | +0.7% | +55.16% | Add |
| 12 | ORKA | Oruka Therapeutics Inc | +0.6% | NEW | New buy |
| 13 | AXSM | Axsome Therapeutics Inc | +0.6% | +70.51% | Add |
| 14 | DYN | Dyne Therapeutics Inc | +0.6% | NEW | New buy |
| 15 | RYTM | Rhythm Pharmaceuticals Inc | +0.5% | +3.30% | Add |
| 16 | APLT | Applied Therapeutics Inc | +0.5% | — | Unchanged |
| 17 | ADGM | Adagio Medical Holdings Inc | +0.5% | NEW | New buy |
| 18 | EWTX | Edgewise Therapeutics Inc | +0.5% | +25.53% | Add |
| 19 | APGE | Apogee Therapeutics Inc | +0.5% | -4.30% | Trim |
| 20 | TIL | Instil Bio Inc | +0.5% | NEW | New buy |
| 21 | ZBIO | Zenas Biopharma Inc | +0.4% | NEW | New buy |
| 22 | EOLS | Evolus Inc | +0.3% | -6.90% | Trim |
| 23 | BHVN | Biohaven Ltd. | +0.3% | — | Unchanged |
| 24 | ALDX | Aldeyra Therapeutics Inc | +0.3% | — | Unchanged |
| 25 | IOVA | Iovance Biotherapeutics Inc | +0.3% | +2.64% | Add |
| 26 | SLNOEUR | Soleno Therapeutics Inc | +0.3% | — | Unchanged |
| 27 | PTGX | Protagonist Therapeutics Inc | +0.3% | +8.34% | Add |
| 28 | ZYME | Zymeworks Inc | +0.2% | +30.72% | Add |
| 29 | PRCT | Procept Biorobotics CORP | +0.2% | +49.84% | Add |
| 30 | XNCR | Xencor Inc | +0.2% | NEW | New buy |
| 31 | ROIV | Roivant Sciences Ltd. | +0.2% | NEW | New buy |
| 32 | AKRO | Akero Therapeutics Inc | +0.2% | +14.33% | Add |
| 33 | EXK | Exact Sciences CORP | +0.2% | NEW | New buy |
| 34 | AMLX | Amylyx Pharmaceuticals Inc | +0.2% | NEW | New buy |
| 35 | FULC | Fulcrum Therapeutics Inc | +0.1% | NEW | New buy |
| 36 | CATBUSD | Astria Therapeutics Inc | +0.1% | — | Unchanged |
| 37 | IMVT | Immunovant Inc | +0.1% | +12.01% | Add |
| 38 | SLDB | Solid Biosciences Inc | +0.1% | — | Unchanged |
| 39 | SYRE | Spyre Therapeutics Inc | +0.1% | -5.23% | Trim |
| 40 | OCUL | Ocular Therapeutix Inc | +0.1% | — | Unchanged |
| 41 | FLNA | Filana Therapeutics Inc | +0.1% | — | Unchanged |
| 42 | TARS | Tarsus Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 43 | NAUT | Nautilus Biotechnology Inc | +0.1% | — | Unchanged |
| 44 | EYPT | Eyepoint Inc | +0.1% | +62.00% | Add |
| 45 | KYMR | Kymera Therapeutics Inc | +0.1% | NEW | New buy |
| 46 | ACRV | Acrivon Therapeutics Inc | 0% | — | Unchanged |
| 47 | PYXS | Pyxis Oncology Inc | 0% | NEW | New buy |
| 48 | CGON | Cg Oncology Inc | 0% | — | Unchanged |
| 49 | ICLR | ICON Public Limited Company | 0% | +41.93% | Add |
| 50 | LXEO | Lexeo Therapeutics Inc | 0% | NEW | New buy |
According to official SEC Form 13F filings, Perceptive Advisors LLC reported a total U.S. public equity portfolio value of $6.7B across 106 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ACLXGBX, NUVL, AM6) accounted for 21.2% of total reported equity market value during Q3 2024.
Top New Position Initiated
PODD
市值: $33.1M
Top Position Liquidated / Trimmed
CERE1EUR
前期市值: $441.4M
During Q3 2024, Perceptive Advisors LLC's top holdings by market value included ACLXGBX (6.9%)、NUVL (6.5%)、AM6 (6.3%). The largest single position, ACLXGBX, represented 6.9% of total portfolio value.
In Q3 2024, Perceptive Advisors LLC made 81 total portfolio adjustments, initiating 15 new buys, adding to 24 positions, trimming 24 holdings, and fully liquidating 18 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.